

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	09/937,840
Filing Date	09/26/2001
First Named Inventor	Patrick Soon-Shiong
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	ABI1550-1 (071243-1404)

RECEIVE

MAY 14 2003

TECH CENTER 1600/2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
cm	A1	5,041,292		Feijen	Aug. 20, 1991	
	A2	5,631,018		Zalipsky et al.	May 20, 1997	
	A3	5,714,166		Tomalia et al.	Feb. 3, 1998	
	A4	5,723,147		Kim et al.	Mar. 3, 1998	
	A5	5,756,537		Gill	May 26, 1998	
	A6	5,766,627		Sankaram et al.	Jun. 16, 1998	
	A7	5,772,992		Bauer et al.	Jun. 30, 1998	
	A8	5,789,248		Fodstad et al.	Aug. 4, 1998	
	A9	6,066,668		Hausheer et al.	May 23, 2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
cm	A10	WO	94/06422		Government of the United States as represented by The Secretary, Department of Health and Human Services	March 31, 1994		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
cm	A11	International Search Report for PCT Application No. PCT/US00/10849	
cm	A12	Supplementary European Search Report for European Patent Application No. EP 00 92 8296.	

Examiner
Signature

cm


Date
Considered

5-24-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for PTO/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/937,840		
		Filing Date	09/26/2001		
		First Named Inventor	Patrick Soon-Shiong		
		Group Art Unit	1614		
		Examiner Name	Unknown		
Sheet	2	of	4	Attorney Docket Number	ABI1550-1 (071243-1404)

RECEIVED

MAY 14 2001
TECH CENTER 1606

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm	A13	Arbuck et al., "Clinical Development of Taxol." Journal of the National Cancer Institute Monographs No. 15, p. 11-24, 1993.	
	A14	Dorr, "Pharmacology of the Taxanes." Pharmacotherapy, 17:965-1045, 1997.	
	A15	Eisenhauer et al., "European-Canadian randomized trial of Paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion." Journal of Clinical Oncology, 12:2654-2666, 1994.	
	A16	Fennelly et al., "Phase I and pharmacologic study of Paclitaxel administered weekly in patients with relapsed ovarian cancer." Journal of Clinical Oncology, 15:187-192, 1997.	
	A17	Fletcher et al., "Antinociceptive effect of bupivacaine encapsulated in Poly(D,L)-Lactide-Co-Glycolide microspheres in the acute inflammatory pain model of carrageenin-injected rats." Anesth. Analg., 84:90-94, 1997.	
	A18	Gianni et al., "Nonlinear pharmacokinetics and metabolism of Paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans." Journal of Clinical Oncology, 13:180-190, 1995.	
	A19	Greco et al., "One-hour Paclitaxel infusions: review of safety and efficacy." The Cancer Journal, 5: 179-191, 1999.	
	A20	Holmes et al., "Final Results: Randomized phase III trial of Paclitaxel by 3-hour versus 96-hour infusion in patients (PT) with MET breast cancer. The long and short of it." Meeting Abstract. Proceedings of the American Society of Clinical Oncology, 16:110a, 1998.	
	A21	Holmes et al., "Phase III trial of pactitaxel (P) administered over 3- or 96-hr for metastatic breast cancer (MBC)." Meeting Abstract. Proceedings of the American Society of Clinical Oncology, 15:106a, 1996.	
	A22	Hainsworth et al., "Carcinoma of unknown primary site: Treatment with 1-hour Paclitaxel, Carboplatin, and extended-schedule Etoposide." Journal of Clinical Oncology, 15:2385-2393, 1997.	

Examiner Signature		Date Considered	5-24-04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 100B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known			
(use as many sheets as necessary)		Application Number	09/937,840		
		Filing Date	09/26/2001		
		First Named Inventor	Patrick Soon-Shiong		
		Group Art Unit	1614		
		Examiner Name	Unknown		
Sheet	3	of	4	Attorney Docket Number	ABI1550-1 (071243-1404)

RECEIVED
MAY 14 2003
TECH CENTER
600/290


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Cm	A23	Hainsworth et al., "Paclitaxel administered by a 1-hour infusion: A Phase 1-11 trial comparing two schedules." The Cancer Journal from Scientific American, 1:281-287, 1995.	
	A24	Hainsworth et al., "Paclitaxel by 1-hour infusion: An Active drug in metastatic non-small-cell lung cancer." Journal of Clinical Oncology, 13:1609-1614, 1995.	
	A25	Hainsworth et al., "Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities." Journal of Clinical Oncology, 15:3464-3470, 1997.	
	A26	Huizing et al., "Pharmacokinetics of Paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients." Journal of Clinical Oncology, 11:2127-2135, 1993.	
	A27	Kearns et al., "Paclitaxel pharmacokinetics and pharmacodynamics." Seminars in Oncology, 22:16-23, 1995.	
	A28	Klaassen et al., "Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer." European Journal of cancer, 32A: 547-549, 1996.	
	A29	Langer et al., "Paclitaxel (P) by 1 or 24 hour (HR) infusion combined with carboplatin @ in advanced non-small cell lung carcinoma (NSCLC): a comparative analysis." Meeting abstract. Proceedings of the American Society of Clinical Oncology, 16:45a, 1997.	
	A30	Lopes et al., "Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines." Cancer Chemotherapy and Pharmacology, 32:235-242, 1993.	

Examiner Signature		Date Considered	5-24-04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Substitute for Form 1449B-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Application Number	09/937,840
		Filing Date	09/26/2001
		First Named Inventor	Patrick Soon-Shiong
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	4	of	4
		Attorney Docket Number	ABI1550-1 (071243-1404)

RECEIVED
MAY 4 2003
TECH CENTER 16001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm	A31	Obtsu et al., "Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion." Clinical Cancer Research, 1:599-606, 1995.	
	A32	Onetto et al., "Overview of taxol safety." Journal of the National Cancer Institute, Monographs No. 15, p. 131-139, 1993.	
	A33	Seidman et al., "One-hour paclitaxel via weekly infusion: Dose-density with enhanced therapeutic index." Oncology, Vol. 12, No. 1, Supplement No. 1, p. 19-22, 1998.	
	A34	Sonnichsen et al., "Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors." Journal of Clinical Oncology, 12: 532-538, 1994.	

Examiner Signature		Date Considered	5-24-04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.